A drug-gene network for understanding drug mechanism of action by Karabulut, Nermin Pinar
A Drug-Gene Network for Understanding
Drug Mechanism of Action
by
NERMN PINAR KARABULUT
Submitted to the Graduate School of Engineering and Natural Sciences
in partial fulﬁllment of





c© Nermin Pnar Karabulut 2012
All Rights Reserved
A Drug-Gene Network for Understanding Drug Mechanism of
Action
Nermin Pnar Karabulut
Computer Science and Engineering, Master's Thesis, 2012
Thesis Supervisor: Asst. Prof. Murat Çokol
Keywords: Chemogenomics, high-throughput screening, biological
networks, biological statistics, chemical structural and side eﬀect similarity
Abstract
Chemogenomics experiments, where genetic and chemical pertur-
bations are combined, provide data for discovering the relationships
between genotype and phenotype. Here, we computationally analyzed
the largest chemogenomics dataset, which combines more than 300
chemicals with virtually all gene deletion strains in the yeast S. cere-
visiae. Traditionally, analysis of chemogenomic datasets has been done
considering the sensitivity of the deletion strains to chemicals, and this
has shed light into drug mechanism of action and ﬁnding drug targets.
We also considered the deletion strains which are resistant to chem-
icals. We found a small set of genes whose deletion makes the yeast
cell resistant to many chemicals. Curiously, these genes were enriched
for functions related to RNA metabolism. Our approach allowed us to
generate a network of drugs and genes that are connected with resis-
tance or sensitivity relationships. As a quality assessment, we showed
that the higher order motifs found in this network make biological
iii
sense. Moreover, by using this network, we constructed a biologically
relevant network projection pertaining to drug similarities, and sub-
sequently analyzed this network projection in detail. We propose the
drug similarity network as a useful tool for understanding drug mech-
anism of action.
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laçlarn Etki Mekanizmalarn Anlayabilmek için laç-Gen A§
Nermin Pnar Karabulut
Bilgisayar Bilimi ve Mühendisli§i, Yüksek Lisans Tezi, 2012
Tez Dan³man: Yrd. Doç. Dr. Murat Çokol
Anahtar Kelimeler: Kemogenomik, yüksek veri taramas, biyolojik a§lar,
biyolojik istatistik, kimyasal yap ve yan etki benzerli§i
Özet
Genetik ve kimyasal kar³klklarn birle³tirildi§i kemogenomik deneyler,
genotip ve fenotip arasndaki ili³kinin ke³fedilmesi için veri sa§lar. Bu ara³tr-
mada biz, 300 tane kimyasala kar³ S. cerevisiae'daki bütün delesyon su³larnn
büyüme bilgisinin içerildi§i, ³u ana kadar üretilmi³ olan en büyük kemogenomik
veriyi hesaplamal olarak analiz ettik. imdiye kadarki kemogenomik veri
analizlerinde hep delesyon su³larnn kimyasallara kar³ 'duyarllk' ili³kisi in-
celenmi³tir ki bu ilaçlarn etki mekanizmalarnn anla³lmasna ve ilaç hede-
ﬂerini bulmaya ³k tutar. Biz ise bunun yannda bir de delesyon su³larnn
kimyasallara kar³ olan 'direnç' ili³kisini inceledik. Öyle bir gen kümesi bul-
duk ki bu genlerin hücreden silinmesinin, maya hücresini birçok ilaca kar³
dirençli kld§n farkettik. lginç bir ³ekilde, bu genlerin RNA metaboliz-
masyla ilgili fonksiyonlarda tesadüfen beklenmeyecek kadar i³levi oldu§unu
bulduk. Bu projedeki yakla³mmz bize ilaçlarn ve genlerin birbiriyle 'du-
yarllk' ve 'direnç' ili³kileriyle ba§land§ bir ilaç-gen a§ olu³turmamz sa§lad.
v
Bu a§a kalite kontrol olarak yapt§mz analizlerde, a§daki yüksek dereceli
motiﬂerin aslnda biyolojik olarak anlam ifade etti§ini farkettik. Bununla
beraber, bu a§ kullanarak ilaç benzerlikleriyle ilgili, biyolojik amaca uygun
bir a§ yansmas olu³turduk, ve sonrasnda bu a§ ayrntl olarak analiz ettik.
Elde etti§imiz bu ilaç benzerlik a§n, ilaçlarn etki mekanizmalarn daha iyi
anlayabilmek için yararl bir araç olarak sunuyoruz.
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1 Introduction
Currently, the trend in drug discovery is the target identiﬁcation [5] which
is based on the assumption that a drug can change the activity of a defected
function by binding to the protein (target) responsible for that particular
function. A common target-based approach is high-throughput screening
(HTS) where numerous chemicals are tested against a chosen target related
to a disease, and observations are made on the inhibition ability of chemicals
[6]. Another approach includes computer-aided models where the library of
chemicals are attempted to dock to the target proteins in silico. These target-
oriented approaches reveal novel compounds increasingly, but only several of
them can be approved due to developmental and experimental costs. Hence,
a reasonable selection of chemicals should be done beforehand to reduce these
costs. On the other hand, the mechanism of action of most US Food and
Drug Administration (FDA)-approved drugs is still unknown despite the use
of them in curing certain diseases [7]. However, in some cases, a cell may
show same response to certain drugs which leads to discovering the drugs
that have similar mechanism, as a result, suggesting candidates of chemicals
to be most likely eﬀective in certain diseases. In addition, similar drugs can
be used as replacement for each other in some cases, such as a drug having
less side eﬀects can be used instead of a similar drug having more side eﬀects.
Therefore, understanding drug mechanism of action is a considerable problem
for drug discovery and therapeutic intervention.
In this study, we propose a drug similarity network that highlights drug
mechanism of action by analyzing a previously published chemogenomic
screening dataset. To the best of our knowledge, sensitivity relationships
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between genes and drugs have been widely used so far. We, however, also
took into account the resistance relationships, and proved that resistance in-
teractions between genes and chemicals have also biological meaning. The
proposed technique involves (i) ﬁnding multi-drug resistance (MDR) and
multi-drug sensitivity (MDS) genes, (ii) constructing a deletion strain-drug
network by using ﬁtness defect scores of deletion strains in the presence of a
particular drug and performing quality assessments to qualify the robustness
of the network, (iii) generating a drug similarity network using sensitivity and
resistance relationships between drugs and deletion strains, again performing
several quality assessments, and quantifying interrelationships between the
similarities found in this network and certain orthogonal datasets, including
chemical structural similarities and side eﬀects similarities of drugs.
2 Background Information and Related Work
In order to better understand the data and the method we have used in this
project, Section 2 gives a background information about chemogenomics,
biological networks and statistics in addition to related works done so far
related to these ﬁelds. Throughout this section, a gene used to represent a
drug target is actually the gene that encodes the protein inhibited by the
corresponding drug.
2.1 Saccharomyces cerevisiae
Saccharomyces cerevisiae is one of the species of yeast. In addition to its im-
portance in industry (i.e. baking and brewing), it is one of the most studied
2
eukaryotic organisms in cell biology owing to its suitability for genetic manip-
ulation, accessibility of its whole genome sequence information [8] and having
many homologs of proteins in human cells, spanning cell cycle proteins, sig-
naling proteins and so on. In addition, yeast is currently the only organism
to be able to detect all targets in the cell in parallel in vivo. As a conse-
quence, many of the chemical genomic studies use S. cerevisiae as the model
organism when we survey in the literature. Moreover, the largest chemoge-
nomics dataset which was published by Hillenmeyer et al., investigates the
genotype-phenotype relationships within S. cerevisiae cells. Therefore, we
exploited the genomic responses of S. cerevisiae cells to chemical compounds
to infer drug mechanism of action throughout this project.
2.2 Chemogenomics
The emerging ﬁeld of chemogenomics investigates the genomic responses to
small chemical compounds. Over the past decade, the chemical-genomic
screening using S. cerevisiae has been leading to discover drug mechanism
of action, primary drug targets, or secondary drug targets, in other words
oﬀ targets that cause unexpected side eﬀects, and also help to reveal genes
buﬀering drug target pathways. In summary, chemogenomics experiments
facilitate to identify cellular responses against small chemical compounds in
vivo [5]. Numerous approaches are implemented to achieve these goals:
1. Haploinsuﬃciency proﬁling (HIP)
2. Homozygous proﬁling (HOP)
3. Chemical genomic-genetic interaction proﬁlings combination
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4. Multi-copy suppression proﬁling (MSP)
5. Chemical-genomic expression proﬁling
Chemical genomic ﬁtness proﬁling screens where two perturbants (deletion
strain and chemical compound) are incorporated, measure the growth re-
sponses of distinct strains, heterozygous (HIP) or homozygous (HOP) dele-
tion collections, in diverse chemical compounds treated cultures in order
to understand drug mechanism of action in addition to gene dispensability,
multi-drug resistance and gene functions within the yeast S. cerevisiae. Un-
derstanding drug mechanism of action contributes to ﬁnd drug targets, to
use combination of drugs in therapeutics or to discover the drug resistant
genes such as antibiotic resistant genes. Moreover, it is noteworthy to state
that comparing similarities of drug chemogenomic ﬁtness proﬁles enables to
discover unknown mechanism of a drug from known mechanism of a drug
[9]. Each deletion collection has a deletion from start to stop codon of a sin-
gle gene, which is further replaced with a unique 20-base-pair DNA tag, or
oligonucleotide barcode whose abundance facilitates to measure the growth
rate of the strains in an ensemble of competing cells under any condition of
choice, using high-density microarrays (or arrays) [10, 1, 11].
Haploinsuﬃciency proﬁling (HIP) which is obtained by deleting one copy
of each gene from the diploid cells [12], is one of the approaches used in
chemogenomics screening to reveal chemical compounds that target proteins
encoded by essential genes by measuring the growth responses of the distinct
deletion strains in the presence of a particular drug because the growth rate
(ﬁtness) of the strain whose deleted gene is encoding the drug target, results
in a further decrease by the drug inhibiting the target protein [12], and
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disappears from the pool over time [5]. This assumption is based on the fact
that one copy of each gene is generally suﬃcient for the optimal growth of the
diploid organisms even though there are rare exceptions. On the other hand,
haploinsuﬃciency, abnormal phenotype caused by loss of function of one copy
of gene, can be identiﬁed in the presence of a particular drug targeting protein
encoded by the deleted gene which further decreases the gene function, in
addition to identiﬁcation of rare haploinsuﬃcient genes under optimal growth
conditions [8]. One of the advantages of the HIP approach is that any prior
knowledge related to compound and its target is not necessary to detect drug
target in this parallel screening [5]. Moreover, a treatment in which the gene
encoding the protein targeted by the drug is absent may help to discover
the secondary drug targets (oﬀ targets) [13]. However, HIP assay has some
disadvantages/shortcomings, too [5]:
• Yeast cells are used in these experiments owing to having human ho-
mologs. However, certain human genes do not have yeast homologs,
resulting in unidentiﬁed targets in human cells.
• HIP approach is based on the assumption that growth of the strain
whose deleted gene is encoding the target protein decreases when it is
exposured to the drug targeting the corresponding gene product. How-
ever, there are some genes whose deletion do not decrease the growth of
the strain when inhibited by the drug. In such cases, the drug targets
cannot be identiﬁed.
• In some cases, deletion of one copy of a particular gene is not enough
to detect drug targets, whereas further deletion (reducing gene dosage
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by more than one copy) of the corresponding gene may highlight the
drug target.
Likewise, the other approach is homozygous proﬁling (HOP) where both
copies of each non-essential gene are deleted from either diploid or haploid
cells. Over time, the growth responses of some strains decrease in the con-
dition of choice and eventually, these strains disappear from the pool like
in HIP assays. However, this time the target genes cannot be identiﬁed di-
rectly due to deleting both copies of the particular gene. On the other hand,
performing the HOP approach, the complete loss of function of the deleted
gene is provided, which subsequently speciﬁes essential genes for growth in
the presence of a particular drug, resulting in a hypothesis that almost all
genes are required for adequate growth in at least one condition [1]. Further-
more, non-essential genes are propounded to subscribe to genetic robustness
[14, 15] and also take a role in drug-target pathways indirectly that makes it
required in the corresponding condition.
In order to ﬁnd drug targets directly by using the HOP approach, it
is combined with genetic interaction data coming from Synthetic Genetic
Analysis (SGA) and this approach may be deﬁned as chemical genomic-
genetic interaction proﬁlings combination. The genetic interaction proﬁle of
a non-essential (or conditionally essential) gene is compared to ﬁtness proﬁles
of non-essential genes in the presence of a particular drug by performing the
HOP approach. The high correlation between these two proﬁles indicates
that the conditionally essential gene is encoding the candidate target protein
of the corresponding drug used in the HOP treatment [16, 5]. However,
the correlation does not need to be a conclusion of inhibition of the target
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gene product by the drug, it may also occur owing to inhibition of gene
products in the target pathways or in the cellular functions [17]. This is
one of the advantages of the chemical genomic-genetic interaction proﬁlings
combination approach. Moreover, once more yeast genetic interaction data
is available, chemical genomic-genetic interaction proﬁlings combination will
be more informative to understand drug mechanism of action [17].
Multi-copy suppression proﬁling (MSP) is obtained by increasing gene
dosage instead of decreasing gene dosage to one copy like in HIP approach or
deleting two copies of each gene such in HOP approach. By increasing gene
dosage, the gene encoding the target protein is over-expressed, resulting in
demonstrating resistance to the chemical treatment [18, 19]. MSP genome-
wide assays competitively screen DNA clone libraries to detect genes showing
resistance to the drug when over-expressed [10].
On the other hand, chemical-genomic expression proﬁling is a genome-
wide approach where only one perturbant (chemical compound) is included
and the genes are in their wild-types. Chemical-genomic expression proﬁling
is performed by examining the mRNA expression proﬁles of the genes in the
presence of chemical compounds or deletion mutants, resulting in identiﬁ-
cation of the gene functions due to the fact that shared cellular functions
most probably show similar expression patterns [20]. The advantage of this
approach is that a transcriptional response causing change in the mRNA ex-
pression proﬁle is not a conclusion of decrease in yeast growth produced by
the inhibiting drug [5]. Therefore, the genes encoding drug targets can be
identiﬁed by performing this approach even though the gene deletions do not
cause a decrease in the strain growth when inhibited by the drug.
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2.2.1 Hillenmeyer et al. dataset
The dataset given by Hillenmeyer et al. [1] is the largest chemogenomics
dataset which combines more than 300 unique set of small chemical com-
pounds and diverse environmental stress conditions with virtually all deletion
strains in the yeast S. cerevisiae. The dataset reports the growth responses of
yeast cells, including whole genome heterozygous and homozygous deletion
collections, in the presence of distinct chemical compounds or environmental
stress conditions. The deletion collections encapsulate approximately 6000
heterozygous gene deletion strains, around 1000 of them are essential genes,
and approximately 5000 viable homozygous deletion strains.
The gene deletion collections are obtained by using four oligonucleotide
barcodes, or tags which have unique 20-base-pair DNAs. Two of the tags are
uptag and downtag on the sense strand and the remaining tags are on the
antisense strand as complementary tags. Using the abundance of these tags
by measuring in microarray, the growth rates of the corresponding deletion
strains are quantiﬁed.
The way this experiment is done is the following: They put all deletion
strains into diﬀerent pools. This means that there should be around 6000
types of yeast cells in each pool corresponding to each deletion strain. Then,
they put diﬀerent chemical compounds into every pool and a competitive
growth occurs in each pool between deletion strains in the presence of a
particular drug. They subsequently compare the growth rate of each dele-
tion strain in the presence of a certain drug, called treatment, with no drug
condition, called control.
Then, the authors give two deﬁnitions: one of them is that a gene deletion
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strain is considered sensitive to a condition (chemical compound) if its growth
rate in the condition is slower than the control (no drug condition). The
second is that some of deletion strains are sensitive to multiple conditions,
hence the deleted genes of these strains are considered to be necessary for
resistance to diverse perturbations. That's why they are mentioned as multi-
drug resistance (MDR) genes, where multiple means more than 20% of all
unique compounds. Moreover, around 50 MDR genes are reported as highly
enriched for functions related to endosome transport, vacuolar degradation,
and transcription [1].
In order to represent the quantiﬁcation of the growth rates of the strains,
z-score and log-ratio values are used. In addition, p-values of the growth
rates are calculated from z-scores using t-distribution test [1].
Conditions spanning some chemical compounds, contain certain repeated
experiments in which same drug in the same concentration is used on several
repeats. The correlation for pairs of replicates is 0.72 which is much better
than random and supports that the data has a small noise and proves the
reproducibility of the experiment (Figure 1).
2.3 Biological Statistics
Biological statistics are widely used to analyze experimental data. In this
project, we also used several statistics methods such as comparing p-values
to extract signiﬁcant results, multiple hypothesis comparison, or using t-
distribution to reveal signiﬁcantly diﬀerent samples. Here, we indicate cer-
tain background information related to these topics. [21] was used to gain
information related to biological statistics given below.
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Figure 1: Distribution of correlation for pairs of replicates [1]. The correlation
between conditions where same drugs are used in same concentration levels, is
0.72 which proves the reproducibility of the experiment given by Hillenmeyer
et al. [1].
2.3.1 Types of variables
The scaling of variables can take up diﬀerent forms [21] e.g. categorical,
ordinal, ratio etc. Here, I characterize variables as categorical and continuous
which are further used throughout the other sections of the thesis.
• Categorical variable, also known as discrete or qualitative variable, is
used to classify observations into a small number of categories. If there
are only 2 categories, then the variable is called dichotomous variable.
On the other hand, nominal variable represents a variable that has two
or more categories such as class information of protein domains etc.
• Continuous variable, also called quantitative variable, is referred to
represent measurable variables that have numerical values such as tem-
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perature, mRNA expression level etc.
2.3.2 Hypothesis testing
The null hypothesis generally corresponds to the statement that things are
same as each other, or there is not any statistically signiﬁcant diﬀerence
between two measured quantities. The alternative hypothesis, on the other
hand, posits that things are diﬀerent from each other. The aim of the statisti-
cal analysis is to capture whether the observed property is diﬀerent from the
expectation under the null hypothesis. If diﬀerent, the null hypothesis can
be rejected. In data analysis, the alternative hypothesis is more appealing
since it highlights into exciting discoveries. Therefore, one should attempt to
capture interesting patterns included in the data, suggesting the alternative
hypothesis. However, it is noteworthy to state that the probability of getting
a diﬀerence between two samples, just by chance, must be calculated if the
null hypothesis is really true. The null hypothesis can be rejected only if this
probability is lower than a theoretical p-value, or signiﬁcance level, which
should be decided before the analysis (See Section 2.3.3).
2.3.3 P-values and signiﬁcance levels
A p-value is the probability of getting the observed or a more extreme out-
come when the null hypothesis is true [21]. Two types of probabilities can
be examined: one-tail probability and two-tail probability. If the p-value is
calculated as the probability of getting the observed result, or either less or
more than the observed result, it would be one-tailed probability. However,
when the both tails (suﬃciently large and suﬃciently small) are taken into
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Figure 2: Probability from both suﬃciently large (right-tail probability) and
suﬃciently small (left-tail probability) regions on the normal distribution [2].
account, the two-tailed probability is assumed as in Figure 2 [22].
The conventional signiﬁcant level of p-value in biology is 0 .05 which
means that if the probability to observe an outcome is less than 0 .05 , the
null hypothesis can be rejected, as a result the alternative hypothesis is true.
On the other hand, if the probability is greater than or equal to 0 .05 , the null
hypothesis cannot be rejected. 0 .05 signiﬁcance level states that even though
the null hypothesis is true, there is 5% chance to reject the null hypothesis
which corresponds to false positive, or Type I, error. On the other hand, if
the null hypothesis is not rejected even if the alternative hypothesis is true,
false negative, or Type II, error occurs [21] which is shown in Table 1.
If the chosen signiﬁcance level is higher than 0 .05 , the chance of a false
positive, wrong conclusion, is increased, whereas the chance of false neg-
ative is decreased. However, if the chosen signiﬁcance level is lower than
0 .05 , while detecting false positive is decreased, this time the chance of false
negative is increased. Therefore, there is a threshold when choosing the sig-
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Alternative (real) Null (real)
Alternative (analysis) Null hypothesis correctly rejected False positive, Type I error
Null (analysis) False negative, Type II error Null hypothesis correctly retained
Table 1: Tabulated relation between reality and statistical analysis
niﬁcance level, which should be optimized according to the costs of false
negatives and false positives inherited in the data.
2.3.4 t-Distribution test
Student t-test is one of the t-distribution that is employed to compare the
means of two samples [21]. Student t-test is used when there are two types of
variables: nominal variable and measurement variable. The nominal variable
has two categorical values [21]. Then, using Student t-test, the means of
two samples whose elements are measurement variable, are compared. As
expected, the null hypothesis of the t-test is that the mean values of two
samples are same.
2.3.5 Multiple comparisons
When there are multiple hypothesis that should be taken into account, the
signiﬁcance level should be chosen carefully. This is an open research area
that there is not any universally accepted approach to decide the signiﬁcance
level in multiple hypothesis problem.
1. Bonferroni correction, is one of the approaches for multiple compar-
isons that uses a signiﬁcance level found as dividing the conventional
p-value by the number of statistical tests. As a result, the signiﬁcance
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level is chosen lower than conventional p-value 0 .05 , which would fur-
ther decrease the chance of false positives. However, in some cases,
there are numerous number of statistical tests which concluded with
a very small p-value (Let's say there are 1000 tests, so p-value would
be equal to 0 .05/1000 = 0 .00005 ) that increases the chance of false
negatives this time. BenjaminiHochberg procedure can be used as an
alternative approach in such cases.
2. Holm-Bonferroni method is similar to Bonferroni method, but has
slight diﬀerence. The algorithm of Holm-Bonferroni method is given in
Algorithm 1.
3. BenjaminiHochberg procedure controls the proportion of signiﬁ-
cant results which are actually false positives, by setting false discovery
rate to a constant percentage. The algorithm of BenjaminiHochberg
procedure is given in Algorithm 2.
2.4 Biological Networks
Biological networks facilitate to characterize many complex biological sys-
tems. Categorizing the biological networks into 2 classes reveals molecular
networks such as protein-protein interaction networks, metabolic networks,
regulatory networks, RNA networks etc., and phenotypic networks, includ-
ing co-expression networks, genetic interaction networks, chemical-genetic
networks and so on [24]. The great amount of the studies to date are used
Escherichia coli and Saccharomyces cerevisiae as the model organisms owing
to the advantage of available set of data for these organisms. However, after
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Algorithm 1 Holm-Bonferroni algorithm [23]
Input:
• k : the number of hypothesis to be tested
• α: the signiﬁcance level
• P : the set of p-values of null hypothesis
Output: The rejected null hypothesis
1. Order p-values in the set P from smallest to largest
2. Compare the smallest p-value, p of the set P to α/k
3. If p is smaller than α/k ,
(a) Reject null hypothesis
(b) Swap k with k − 1
(c) Exclude the smallest p-value, p from the set P
(d) Return to step 1
4. Else, stop. None of the remaining null hypothesis can be rejected.
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Algorithm 2 BenjaminiHochberg algorithm [21]
Input:
• i : ranks of p-values
• m: total number of hypothesis to be tested
• P : the set of p-values of null hypothesis
• Q : the chosen false discovery rate
Output: the rejected null hypothesis
1. Order p-values in the set P from smallest to largest. The smallest
p-value has rank of i = 1, the second has rank of i = 2, and so on
2. Compare each p-value, p in the set P to (i/m)∗Q
3. The largest p-value that has p < (i/m)∗Q is signiﬁcant
4. The other p-values smaller than the p-value, p found in step 3 are also
signiﬁcant.
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completion of the Human Genome Project, the quantity of data concern-
ing to human cells is increased, resulting in better investigation of networks
pertaining to human cells [24]. Nevertheless, the emergence of advances in
network theory highlights certain principles related to network topology [24],
for instance, ability to identify the eﬀect of a randomly perturbed node or
ability to discover the existence of certain patterns in the network. In the
following, I specify the most important principles to analyze and to reveal
certain characteristics of the biological networks.
2.4.1 Degree and degree distribution
According to edge types, a network can be classiﬁed into two diﬀerent cat-
egories: Directed network and undirected network. In directed networks,
links have directions, and each node has an incoming degree and an outgoing
degree which show the number of links coming to and leaving from the cor-
responding node, respectively. On the other hand, in undirected networks,
the number of links that a particular node has, constitutes the degree of the
corresponding node [4].
The average degree of an undirected network is deﬁned as:
< k > =2 ∗ L/N , where:
• <> denotes the average
• k is the degree
• L is the total number of links in the network
• N is the total number of nodes in the network
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The degree distribution of a network, P(k), corresponds to the probability




• P(k) is the degree distribution of nodes having k = 1, 2, ..
• N (k) is the count of nodes having k = 1, 2, ..
• N is the total number of nodes in the network
P(k) is used to identify the topological type of the network, which is explained
in Section 2.4.3 in detail.
2.4.2 Clustering coeﬃcient
The clustering coeﬃcient gives information about how well the neighborhoods
of a particular node are connected to each other. In order to quantify this
phenomenon, the number of triangles that go through the corresponding node
is determined as:
CD = [2 ∗ nD]/[k ∗ (k − 1)], where:
• CD is the number of triangles go through node D
• k is the number of links node D has
• nD is the number of links connecting k neighbors of node D
If clustering coeﬃcient of node D equals to or is in proximity of 1, then node
D is at the center of a fully-connected network or tending to be a center
node, called as hub. In contrast, if the clustering coeﬃcient equals to 0
or is in proximity of 0 , then node D is either isolated or part of a slack
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interlinked network. The average clustering coeﬃcient over all nodes of the
network,< C >, characterizes the network modularity [25].
Moreover, using above information, C (k) is deﬁned as the average clus-
tering coeﬃcient of nodes having k = 1, 2, .. links. C (k) is independent of
the size of the network likewise P(k) [4], hence, C (k) and P(k) are both used
to detect network characteristics (See Section 2.4.3).
2.4.3 Network types
Characterizing the degree, k , of individual nodes reveals general characteris-
tics of the network. For instance, in certain networks, most of nodes have ap-
proximately same number of links which equal to the average degree, < k >,
of the network, whereas scarce of nodes have links more or less than the av-
erage distribution. This type of node's degrees follow a Poisson distribution,
and the type of the network is deﬁned as Random Network.
However, many networks, spanning especially biological networks, contain
a few nodes having many more links than the average node has [26]. Such
nodes constitute the hubs of the network and hold the network together,
suggesting that the nodes represented by these hubs must have a special and
important role [27]. The hubs can be classiﬁed into 2 categories:
• Party hubs, take role inside modules and in coordinating certain cellular
processes as a local coordinator [28, 29]
• Date hubs, connect distinct processes as a global coordinator [28, 29]
Nevertheless, in the networks containing hubs, the number of nodes having
exactly k links which also means the degree distribution P(k), demonstrates
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a power law:
P(k) ∼ k−γ, where:
• k is the degree of the node
• γ is the degree exponent
• P(k) is the degree distribution of nodes having k = 1, 2, ..
These types of networks having a power degree distribution, are deﬁned as
Scale-free networks. Meanwhile,γ value is generally between 2 and 3 in most
of the networks [4, 26]. Notably, it is also noteworthy to state that the smaller
γ value is more important in terms of the role of the hubs because it means
that the largest hub is linked with a large amount of all nodes in the network
[4].
2.4.4 Network motifs
Network motifs are certain n-node subgraphs (n equals to 3 , 4 or more) being
observed more (at a statistically signiﬁcant level) than the randomized where
the randomization is obtained by keeping the network topology same (For
more detail, see Section 4). In order to detect the motifs that describe the
network characteristics, all possible subgraphs are determined and counted
in the real network. After the network is randomized, if the probability of
observing a subgraph in the real network greater number of times than in the
randomized version of the network is lower than a signiﬁcance level (Let's
say conventional p-value 0.05), then these subgraphs are assumed as network
motifs [26, 4]. Due to the fact that most of the network types have speciﬁc
motifs, such as feed-forward loop, bi-fan etc., the dynamical behavior, the
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type and characteristics of the network can be highlighted by detecting the
network motifs [26].
2.4.5 Connected components
A connected component for an undirected network is deﬁned as a subgraph,
where any two nodes in the subgraph are connected to each other by paths
but they are not connected to any other nodes outside of the subgraph. The
largest connected component of a network is called giant component, which
quantiﬁes local functional clustering when comparing to the randomized ver-
sions of the network, obtained by keeping the network topology same [25].
2.4.6 A clique
A clique in an undirected graph is a subset of vertices that every vertex in
the subset is connected to other vertices of the subset by an edge. A clique
can also be called as a complete subgraph. The maximal clique of a network
is a clique of the network which cannot be comprised by any larger clique
within the network [30].
2.4.7 Small-world eﬀect
Most of the complex networks are assumed to demonstrate a small-world
eﬀect which is deﬁned as there are a few links between each pair of nodes
in the network. Thus, this short path length between any pair of nodes
implies that perturbing a particular node causes defects in the activities of




In order to determine the importance of a node in a network, there are numer-
ous types of measurement, including degree centrality, betweenness central-
ity, eigenvector centrality, closeness centrality that all of them use diﬀerent
algorithms to identify the centrality. In our network analysis throughout
this project, we used betweenness centrality to identify importance of nodes.
Once the shortest paths between each pair of nodes in the network are iden-
tiﬁed, the number of shortest paths that pass from a randomly chosen node
is calculated. That number constitutes the betweenness centrality of the
randomly chosen node [31].
2.4.9 PageRank
PageRank is used to identify the important nodes in large networks that its
algorithm is based on webgraphs, where nodes are World Wide Web pages
and directed edges are hyperlinks between pages. The basic assumption
behind this algorithm is that the more web pages a particular web page is
linked with, the more importance that web page would gain. PageRank
can be applied to the biological networks whose edges are directed such as
metabolic networks [32].
2.5 Related Work
In the study proposed by Giaever et al. [8], HIP approach was employed
in chemogenomics analysis in order to identify haploinsuﬃcient genes un-
der optimal growth conditions or stressed conditions. First, they tested six
22
heterozygous strains individually in the presence of a drug which targets the
reduced gene product in the corresponding heterozygous deletion. The results
found from this analysis suggested that decreasing gene dosage contributes to
detect phenotypes. Therefore, they subsequently conducted a larger analysis
by examining 233 S. cerevisiae heterozygous deletion collections in parallel
in the presence of tunicamycin. Haploinsuﬃency was observed in 3 loci in the
presence of drug tunicamycin, one of them is ALG7 which is the known target
of tunicamycin, in addition to the newly discovered 2 loci, YMR007w and
YMR266w. In 2004, they conducted one more HIP approach again, this time
including complete collection of heterozygous deletion strains, 6000 strains,
and 10 chemical compounds [33]. In this analysis, not only are putative and
novel cellular interactions revealed in addition to the known ones, but they
also found a chemical structure shared by three compounds that have diﬀer-
ent therapeutical eﬀect even though all of them inhibit ERG24 heterozygous
deletion strain. Similarly, Lum et al. [34] investigated 3500 heterozygous
deletions in the presence of 78 chemical compounds, reporting many of the
known drug targets.
On the other hand, Parsons et al. [17] performed chemical genomic-
genetic interaction proﬁling combination by incorporating HOP screening
and genetic interactions using Synthetic Genetic Array (SGA) on 4700 vi-
able haploid deletion strains within S. cerevisiae in the presence of 12 diﬀer-
ent chemical compounds. The authors performed two-dimensional hierarchi-
cal clustering of HOP proﬁles with an ensemble of genetic interaction pro-
ﬁles. The results suggested several drug-target pairs to cluster together, and
as a result, contributed to identify uncharacterized genes in speciﬁc roles. In
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2006, they expanded their chemical data to 82 diﬀerent chemical compounds,
performing homozygous proﬁling on 4700 homozygous deletion collections,
and subsequently implementing cluster analysis using two-dimensional hi-
erarchical clustering and probabilistic sparse matrix factorization analysis
[35]. They elucidated novel drug-target relations and eﬀects of certain drugs,
contributing to understand drug mechanism of action in addition to puta-
tive ﬁndings at the end of these analysis. Kapitzky et al. [9] performed
a cross-species chemogenomics screening by combining homozygous deletion
collections of Saccharomyces cerevisiae and Schizosaccharomyces pombe. By
combining deletion strains of both species allowed them to get more accu-
rate ﬁndings related to drug mechanism and to observe more conservation
between two species in compound-functional module relation rather than
compound-gene relation.
Hillenmeyer et al. employed the largest chemogenomics screening to date
by combining HIP and HOP approaches and including 5000 homozygous
deletion strains, 6000 heterozygous deletion strains, 1144 environmental
stress conditions and small chemical compounds where over 300 of them are
unique (See Section 2.2.1 for more detail).
Hoon et al. [10] integrated three genome-wide screens, including homozy-
gous proﬁling (HOP), heterozygous proﬁling (HIP) and multi-copy suppres-
sion proﬁling (MSP) in order to identify targets and to analyze cellular pro-
cesses. They proﬁled 6000 strains against 200 chemical compounds.
Hughes et al. [20] studied chemical-genomic expression proﬁling by creat-
ing a compendium of gene expression proﬁles, including 300 mutant expres-
sion proﬁles and numerous drug treatments. They elucidated the correlation
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between mRNA expression proﬁles of mutants and known drugs, in addition
to identiﬁcation and experimental conﬁrmation of eight uncharacterized open
reading frames (ORF) required for certain cell processes.
In 2010, Hillenmeyer et al. [12] computationally analyzed the previously
obtained chemogenomics data in [1]. First, they deﬁned co-ﬁtness metric
which gives the correlation of growth rates of deletion collections in the pres-
ence of diﬀerent compounds, and subsequently used this metric to quan-
tify how well it predicts gene functions in comparison to other large scale
datasets, resulting in an observation of better predictions. Moreover, they
implemented a machine-learning approach to predict drug-target interactions
by using combination of ﬁtness defect scores of strains in the condition of
choice, chemical structural similarity between drugs, and therapeutic class
information of drugs. The results of the machine-learning approach were cer-
tain known or robust novel drug-target predictions where two of top 12 novel
predictions were further veriﬁed experimentally: nocodazole with Exo84 and
clozapine with Cox17. Nevertheless, 5 of top 12 predictions were validated
by literature ﬁndings.
3 Motivation and Contribution of the Thesis
The prevailing picture from the previous works given in Section 2.5 is that
most of the chemogenomics studies have produced the chemogenomics data
and have inferred certain observations according to the analysis of the exper-
iments. However, to the best of our knowledge, except a handful of studies
as in [12], [9], [35], there are no studies applying any statistical, machine-
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learning or network based approaches to neither the previously produced
chemogenomics data nor the data produced by themselves. A machine learn-
ing based approach was implemented only in [12], where the ﬁtness defect
scores of strains in the condition of choice, therapeutic class information of
drugs, and chemical structural similarity between drugs were combined to
predict novel drug-target interactions. From the literature search, we ob-
served certain network-based studies related to drug-target interaction data
[36, 25], contributing to understand the relationship between drug targets and
disease-gene products, also to discover unknown drug targets using known
ones. However, the drug-target data information used in these works is not
purely inferred from chemogenomics experiments. The drug-target interac-
tion information is taken from DrugBank or such repository websites where
interactions may be obtained using not only chemogenomics experiments
but also several types of biological or computational studies. Therefore, all
of them motivated us to propose the approach given in Section 4 which an-
alyzes chemogenomics data by using network-based analysis and statistical
tools in order to better understand drug mechanism of action.
The proposed method enables to reveal unknown drug mechanism of ac-
tions, and to discover genes that have similar responses in the cellular context.
In this research, we constructed a drug similarity network from the deletion
strain-drug interaction network that reveals signiﬁcant similarities between
drugs which subsequently help to discover certain unknown eﬀects of a drug
from the most similar drug whose mechanism is known.
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4 Methods & Materials
The method proposed in this work can be summarized as in the ﬂowchart
given in Figure 3, and each step is explained in detail in the following sections.
Besides, it is noteworthy to remark that the Hillenmeyer et al. dataset is cho-
sen as the chemogenomics dataset to analyze in the proposed method owing
to being the largest chemogenomics dataset, and also being reproducible (For
more detail, see Section 2.2.1).
4.1 Fitness Scores Combination
In Hillenmeyer et al. dataset, same drugs in diﬀerent concentration levels
were sometimes used. Moreover, as we mentioned in Section 2.2.1, there
are also some repeated experiments where a same drug was used in same
concentration levels to demonstrate the reproducibility of the experiment.
However, we are interested in inferring relationships between chemical com-
pounds (drugs) and genes in this project. Therefore, we combined the ﬁtness
scores represented with z-scores of such experiments. In statistics, the widely
used methods for combination are Fisher's method which is based on p-values,
and Stouﬀer's method to get one unique z-score from diﬀerent z-score values.
As we used ﬁtness scores data represented by z-scores, we combined z-scores
of such repeated experiments by using Stouﬀer's method whose equation is
given in Equation 4.1 where k is the number of repeated experiments, Zi is
the z-score of the corresponding experiment, and Z is the ﬁnal z-score for
such repeated experiments.
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Figure 3: The ﬂowchart of the proposed methodology
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Once collapsing such repeated experiments using Stouﬀer's method, we
were able to have a unique set of results for each drug and to reduce the
condition number to ~300 from ~700, all of which are unique compounds.
4.2 Deﬁnition of Resistance and Sensitivity
As mentioned in Section 2.2.1, in the dataset we used, all the deletion strains
were grown competitively in diﬀerent pools including diﬀerent chemical com-
pounds, and then, the growth rate of each strain in the presence of a particu-
lar drug (treatment) was compared with the growth of that strain in no drug
condition (control). If a deletion strain grows slower than normal (no drug
condition) in the presence of a particular drug, we infer a `sensitivity' rela-
tionship between this particular deletion strain-drug pair which is the given
deﬁnition in Hillenmeyer et al. article [1]. On the contrary, if a deletion
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strain grows faster than normal in the presence of a particular drug, we infer
a `resistance' relationship between this particular deletion strain-drug pair.
4.2.1 Illustration for inferring resistance and sensitivity relation-
ship
Figure 5 illustrates a basic example for how the experiment was done and
how the relationships were decided. First tube (pool) represents the control
condition where all yeast strains grow competitively without any chemical
compound. In the second tube, when drug 1 is put, deletion strain B grows
faster than normal (no drug condition). However, deletion strain A grows
slower, no strain A in the second tube anymore.
It can subsequently be concluded that deletion strain B grows faster than
normal in the presence of drug 1. In addition, deletion strain A grows slower
than normal in presence of drug 1.
In our study, we deﬁne that deletion B is resistant to drug 1, and deletion
strain A is sensitive to drug 1. And we infer a resistance relationship between
strain B-drug 1, and a sensitivity relationship between strain A-drug 1.
In the third tube, deletion strain A grows faster than normal (no drug
condition) in the presence of drug 2 this time. However, deletion strain C
grows slower, no strain C in the third tube anymore.
Similar to before, we infer a resistance relationship between strain A-drug
2, and a sensitivity relationship between strain C-drug 2.
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Figure 5: Example for how to infer resistance and sensitivity relationships
between deletion strains and drugs. First tube (pool) represents the control
condition where all yeast strains grow competitively without any chemical
compound. In the second tube, when drug 1 is put, deletion strain B grows
faster than normal (no drug condition). However, deletion strain A grows
slower, no strain A in the second tube anymore. In the third tube, deletion
strain A grows faster than normal in the presence of drug 2 this time. How-
ever, deletion strain C grows slower. In conclusion, it can be inferred from
the second tube that deletion strain B is resistant to drug 1, whereas deletion
strain A is sensitive. Looking at the third tube, we can say that drug 2 has
resistance and sensitivity relationships with deletion strain A and deletion
strain C, respectively.
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4.3 MDR and MDS Genes Detection
In Hillenmeyer et al. dataset, some of deletion strains are sensitive to multi-
ple conditions, hence the deleted genes of these strains are considered to be
necessary for resistance to diverse perturbations. That's why they are men-
tioned as multi-drug resistance (MDR) genes, where multiple means more
than 20% of all unique compounds (See Figure 6). Similar to MDR genes,
we can also speak of multi-drug sensitive (MDS) genes whose deletion strains
were resistant to multiple drug conditions, which mean that the deleted genes
of these strains seem to be necessary for sensitivity to diverse perturbations
(See Figure 7).
However, here is the issue that a threshold must be chosen to decide
whether a deletion strain is sensitive or resistant to a condition. We use the
same sensitivity threshold used by Hillenmeyer et al. in their study, p < 0.01,
but the corresponding z-score, z > 2 .33 was set as the threshold in our study
as we used the ﬁtness score data represented by z-scores. In order to identify
resistance interactions, z < −2 .33 which is the correspondence of upper tail
p-value p > 0 .99 , was chosen.
In Algorithm 3, the detail of referring sensitivity and resistance interac-
tion types between deletion strains and compounds are given. The output
of the Algorithm 3 is matrix D ′, where the entity d ′(i , j ) demonstrates resis-
tance (1 ), sensitivity (−1 ) or no interaction (0 ) information between deletion
strain i and compound j .
Once deﬁning sensitivity and resistance interactions between deletion
strains and compounds, it is straightforward to ﬁnd deletion strains that
are sensitive or resistant to more than 20% of the unique conditions.
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Figure 6: Multi-drug resistance (MDR) genes. x-axis shows the percentage
of conditions, whereas y-axis shows the percentage of genes. Genes showing
sensitivity to greater than 20% of all unique conditions at z > 2 .33 , are
assumed as MDR genes.
Figure 7: Multi-drug sensitive (MDS) genes. x-axis shows the percentage
of conditions, whereas y-axis shows the percentage of genes. Genes showing
resistance to greater than 20% of all unique conditions at z < −2 .33 , are
assumed as MDS genes.
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Algorithm 3 Assigning resistance and sensitivity interactions to detect
multi-drug resistance (MDR) and multi-drug sensitive (MDS) genes. Fitness
defect z-scores of the deletion strains are transformed into discrete numbers
at given thresholds for resistance and sensitivity interactions. The output
of the algorithm is matrix D ′, where the entity d ′(i , j ) demonstrates resis-
tance (1 ), sensitivity (−1 ) or no interaction (0 ) information between deletion
strain i and compound j .
Input:
• z − low score
• z − up score
• Matrix D , showing continuous ﬁtness scores (z-scores) of deletion
strains in rows against chemical compounds in columns
Output: Matrix D ′, showing categorical ﬁtness scores of deletion strains in
rows against chemical compounds in columns
1. For each entity d(i , j ) in matrix D , do
(a) if d(i , j ) < z − low, then assign 1 to d ′(i , j ) in matrix D ′
(b) if d(i , j ) > z − up, then assign −1 to d ′(i , j ) in matrix D ′
(c) else, assign 0 to d ′(i , j ) in matrix D ′
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Figure 8: Gene Ontology (GO) enrichment test for multi-drug sensitive genes
(MDS). Results are obtained by using the tool: FuncAssociate 2.0 [3]. MDS
genes are found highly enriched for RNA metabolism related functions.
Around 50 MDR genes were found highly enriched for functions related to
endosome transport, vacuolar degradation, and transcription in Hillenmeyer
et al. [1] article. We also found around 10 MDS genes highly enriched for
functions related to RNA metabolism (Figure 8). In our further analysis, we
discarded MDR and MDS genes as we are interested in compound-speciﬁc
proﬁles of genes which show growth phenotype to a limited number of con-
ditions.
4.4 Strain-Drug Network Construction
As in the illustration given in Figure 5, sensitivity and resistance relationships
can be thought as a network, where drugs and deletion strains constitute the
nodes of the network, and resistance and sensitivity relationships between
drugs and deletion strains are the edges of the network. The network itself
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is a bipartite graph consisting of deletion strain-drug interactions where a
deletion strain and a drug are linked to each other with either a resistance
or sensitivity relation, whereas there is no edge between any of two dele-
tion strains or between any of two drugs [25]. However, there is again the
same issue as in MDR-MDS detection that a threshold must be set to de-
cide whether a growth rate shows sensitivity or resistance. As diﬀerent from
Algorithm 3, we did not set a general threshold to use in every growth rate.
Since we would subsequently construct a drug similarity network (See 4.5)
in the next step, we wanted to make all compounds equally related to the
deletion strains. By doing this, the suggesting results that come from drug
similarity network would have equal priors.
In Algorithm 4, the detail of referring sensitivity and resistance interac-
tion types between deletion strains and compounds are given. Likewise the
Algorithm 3, the output of the Algorithm 4 is matrix D ′, where the entity
d ′(i , j ) demonstrates resistance (1 ), sensitivity (−1 ) or no interaction (0 )
information between deletion strain i and compound j .
By performing Algorithm 4, a deletion strain is assigned as sensitive or
resistant to a condition if its ﬁtness defect z-score is in the top one hundred
ﬁtness scores or the lowest one hundred ﬁtness scores, respectively of that
particular condition. The top or lowest one hundred z-scores per drug were
chosen because by choosing less z-scores such as the top or lowest ﬁfty z-scores
per drug, we could not obtain signiﬁcantly biologically meaningful higher
order motifs whose details are given in Section 4.4.1. Besides, in Figure 9,
the top and lowest one hundred ﬁtness growth z-scores per drug are shown.
As seen from the ﬁgure, certain drugs have high diﬀerence between chosen
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z-scores, whereas the other drugs have less.
Algorithm 4 Assigning resistance and sensitivity interactions to construct
the deletion strain-drug network. A deletion strain is assigned as sensitive or
resistant to a condition if its ﬁtness defect z-score is in the top one hundred
ﬁtness scores or the lowest one hundred ﬁtness scores, respectively of that
particular condition. The output of the algorithm is matrix D ′, where the
entity d ′(i , j ) demonstrates resistance (1 ), sensitivity (−1 ) or no interaction
(0 ) information between deletion strain i and compound j .
Input:
• Matrix D , showing continuous ﬁtness scores (z-scores) of deletion
strains in rows against chemical compounds in columns
Output: Matrix D ′, showing categorical ﬁtness scores of deletion strains in
rows against chemical compounds in columns
1. for each column (condition) j in matrix D , do
(a) Add the indexes of the highest 100 z-scores in column j to the set
S
(b) for each index i in S
i. Assign −1 to the entityd ′(i , j ) of the matrix D ′
(c) Add the indexes of the lowest 100 z-scores in column j to the set
S ′
(d) for each index i in S ′
i. Assign 1 to the entityd ′(i , j ) of the matrix D ′
(e) Assign 0 to the remaining elements of j . column of D ′matrix
4.4.1 Quality assessments
We did two quality assessments pertaining to the deletion strain-drug net-
work in order to qualify the robustness of the network.
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Figure 9: The top and lowest one hundred ﬁtness z-scores per drug which
are considered sensitive and resistant interactions, respectively obtained by
performing Algorithm 4. Every red dot represents a z-score. x-axis shows
the drug number, whereas y-axis shows the values of the top and lowest one
hundred z-scores of the corresponding drug. As seen, certain drugs have high
diﬀerence between chosen z-scores, whereas the other drugs have less.
First, as in Figure 10, for each drug pair, we counted the number of dele-
tion strains that 2 drugs have resistance (R) relationships with, or sensitivity
(S) relationships with, in order to investigate whether there is a relation
between resistance and sensitivity interactions.
Second, we wanted to understand if any of the higher order motifs in
this network is enriched or depleted. We counted the number of motifs,
consisting of 2 drugs and 2 deletion strains, and R or S relationships between
them in the real deletion strain-drug network. The motifs are demonstrated
in Figure 11. In the ﬁrst motif, drug1 and drug2 have resistance edges to
both of the strains, whereas in the seventh motifs, drug1 and drug2 have
sensitivity edges to both strains. In the second motif, drug2 has resistance
edges to both of the strains, but drug1 has sensitivity relationship to strainA,
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Figure 10: Motifs that are used in quality assessment 1. In this example, if
the deletion strains in strain set1 are resistant to both of drug1 and drug2, the
number of deletion strains in strain set1 constitutes the RR motif number for
drug1-drug2 pair. SS motifs for drug1-drug2 pair can be counted similarly.
Overall, this counting is done for all drug pairs.
and resistance relationship to strainB. In the third motif, both drug1 and
drug2 have resistance edges to strainA, but have sensitivity edges to strainB.
In motif 4 , drug1 has sensitivity relationship to strainA, and has resistance
relationship to strainB, but drug2 has opposite relations to these strains. In
the ﬁfth motif, drug1 has sensitivity relationships to both of the strains, but
drug2 has resistance edges to them. On the other hand, in motif 6 , drug1
has resistance edge to strainA but sensitivity edge to strainB, whereas drug2
has sensitivity edges to both of the strains.
We analyzed these motifs statistically. For example, if drug1 has an R
(resistance) relationship with deletion strainA and an S (sensitivity) relation-
ship with deletion strainB, we expect to observe that another drug which has
an R relationship with deletion strainA, also has an S relationship with dele-
tion strainB. We did such analysis by comparing the observations of motifs
in the real network to those in randomized versions of the network. The
processes are demonstrated with the ﬂowchart given in Figure 4.
Network randomization was done by edge swapping with the following
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steps:
• For 700000 iterations
 Choose 2 edges from the bipartite network randomly
 Swap the endpoints of the edges
700000 times edge swapping were done which are approximately 10 times
of total edge number of the network. Eventually, one random network was
constructed. Network topology remained same since edge distribution, the
numbers of sensitivity and resistance edges per drug and per deletion strain
were still same. We did such randomization 1000 times to identify the signif-
icance of the higher order motifs in the whole network. fold enrichment value
which shows the enrichment and depletion values of the motifs in comparison
to the randomized versions of the network, and empirical p-value for each










• i = 1, 2, 3, .., 7 denotes the higher order motif number
• pi is the p-value of Motifi
• foldenrichmenti is the fold enrichment value of Motifi
• sreal(Motifi) is the number of occurrences of Motifi in the real network
• srandomj (Motifi) is the number of occurrences of Motifi in the j th ran-
dom network
• R is the set of random networks
• N is the size of the set R that equals to the number of random networks
• length{srandomj (Motifi) ≥ sreal(Motifi)} is the count for cases where the
number of occurrences ofMotifi in randomized network j is bigger than
or equal to the number of occurrences of Motifi in the real network
• length{srandomj (Motifi) ≤ sreal(Motifi)} is the count for cases where the
number of occurrences ofMotifi in randomized network j is smaller than
or equal to the number of occurrences of Motifi in the real network
Comparison with the conventional p-value 0 .05 is not enough here to decide
signiﬁcance level of the empirical p-values since multiple hypothesis were
taken into account. There are 7 motifs which may either be depleted or
enriched, hence, 14 hypothesis were compared in this analysis. For multiple
comparison, Bonferroni Correction method given in Section 2.3.5 was used
to ﬁnd cutoﬀ p-value that gives 0 .05/14 = 0.0035 rather than conventional
0 .05 . Moreover, since 1/0 .0035 = 285 , 285 randomizations are enough to
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test the signiﬁcance of an obtained p value. However, we made 1000 ran-
domizations.
Figure 11: The higher order motifs of the deletion strain-drug network. 7
diﬀerent higher order motifs can be deﬁned by using 2 drugs, 2 deletion
strains and 2 types of edges. In the ﬁrst motif, drug1 and drug2 have resis-
tance edges to both of the strains, whereas in the seventh motifs, drug1 and
drug2 have sensitivity edges to both strains. In the second motif, drug2 has
resistance edges to both of the strains, but drug1 has sensitivity relationship
with strainA, and resistance relationship with strainB. The other motifs can
also be analyzed similarly.
4.5 Drug-Drug Similarity
As the next step, we subsequently generated a drug similarity network from
the bipartite deletion strain-drug graph. If a drug pair has frequently S or
R relationships to the same set of deletion strains, we assume this drug pair
as similar to each other in the drug similarity network. On the other hand,
if a drug pair has inverse relationships to the same set of deletion strains,
such as one of the drugs has R relations, whereas the other has S relations
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to the same deletion strains, we consider the drugs in this pair diﬀerent to
each other. By doing this, we built up the drug similarity network shown
in Figure 14, which demonstrates the similarities and dissimilarities between
drugs.
However, in order to be able to consider two drugs similar or diﬀerent
to each other, a threshold must be used to decide similarity or dissimilar-
ity because it is not enough to say that a drug pair is similar or diﬀerent
to each other by only observing limited number of shared deletion strains.
Therefore, we randomized the deletion strain-drug network, and calculated
a p-value and a fold enrichment value for each drug pair in the network as in
Equation 4.3 and Equation 4.2, respectively. However, when assessing signif-
icance for each drug pair, 1000 randomizations as in higher order motifs were
not enough since there are much more hypothesis to test. As there are ∼ 330
chemical compounds used in Hillenmeyer et al. dataset, we have ∼ 55000
drug pairs to test which reduce the signiﬁcant cutoﬀ p-value substantially,
leading to much more randomizations. In detail, since we have ∼ 55000 hy-
pothesis to compare, 0 .05/55000 = 9 .09e − 7 must be the signiﬁcant cutoﬀ
p-value. In order to be able to compare to 9 .09e − 7 signiﬁcant level, at
least 1/9 .09e − 7 = 1100000 randomizations must be done. On the other
hand, more than 1000 randomizations of the deletion strain-drug network
and counting the number of motifs for each drug pair are computationally
intensive processes. However, after randomizations, almost same number of
motifs were observed for each drug pair in the network due to the fact that
we deﬁned same number of sensitivity and resistance interactions for each
drug pair in Algorithm 4 which also means that all drug pairs have same
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number of links to each other, hence, lose their speciﬁcity in the network,
leading to a type of random network. Therefore, we concluded that if we
randomized the real network 500 times, we would have actually ∼ 27000000
randomizations owing to having ∼ 55000 drug pairs, meaning that each drug
pair is one randomization result. This intuition provides us to get much more
randomization results in a computationally non-intensive way.
Then, p-value and fold enrichment value for each drug pair were calculated
by comparing the motif number of similar and diﬀerent edges in the real
network to number of those in ∼ 27000000 random networks.
Eventually, we converted strain-drug network to a drug similarity network
by comparing the p-value and fold enrichment value of each similar and
diﬀerent interactions of each drug pair to < 9.09e− 7 and > 5 , respectively.
4.5.1 Quality assessment
Once the drug similarity network was constructed, as a quality assessment, we
again wanted to understand if any of the higher order motifs in this network
is enriched or depleted. However, this time we counted the number of motifs,
consisting of 3 drugs linked with similar or diﬀerent relationships as shown
in Figure 12. We did such analysis by comparing the observations of motifs
in the real network to those in randomized versions of the network as shown
with the ﬂowchart given in Figure 4. However, network randomization of the
drug similarity network was done with the following steps:
• For 10000 iterations
 Choose 2 edges, both similar or both diﬀerent, from the drug
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similarity network randomly
 Swap the endpoints of the edges
10000 times edge swapping were done which are approximately 10 times
of total edge number of the drug similarity network. Eventually, one ran-
dom network was constructed. Network topology still remained same. We
did such randomizations 1000 times, and calculated a p-value and a fold
enrichment value for each of the higher order motif by using the equations
given in Equation 4.3 and Equation 4.2, respectively. Comparison with the
conventional p-value 0 .05 is again not enough here to decide signiﬁcance
level of the empirical p-values since multiple hypothesis were taken into ac-
count. There are 4 motifs which may either be depleted or enriched, hence, 8
hypothesis were compared in this analysis. For multiple comparison, Bonfer-
roni Correction method given in Section 2.3.5 was used to ﬁnd cutoﬀ p-value
that gives 0 .05/8 = 0.006 rather than conventional 0 .05 . Moreover, as
1/0 .006 = 158 , 158 randomizations are enough to calculate the empirical
p-value. However, we again made 1000 randomizations as in randomization
of deletion strain-drug network.
Besides, the randomized versions of the real network which are used to
calculate the signiﬁcance of subgraphs with 3 nodes (motifs), also keep the
same number of occurrences of all subgraphs with 2 nodes of the real network
[26].
4.5.2 Chemical structural similarity
Once we found similarities and dissimilarities between drugs by inferring from
the drug similarity network, we wanted to compare these similarities with the
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Figure 12: The higher order motifs of the drug similarity network. 4 diﬀerent
higher order motifs can be deﬁned by using 3 drugs and 2 diﬀerent types of
edges. In the ﬁrst motif all drugs are diﬀerent from each other, whereas in
the fourth, all of them are similar. The other motifs can also be analyzed
similarly.
chemical structural similarities of the chemical compounds.
Molecular ﬁngerprints are one of the properties to encode the structure
of a molecule. A series of binary digits (bits) are the widely used type of
ﬁngerprints format that represent the presence or absence information of
certain substructures in the molecule. The similarity between two molecules
can be identiﬁed by comparing their ﬁngerprints.
We represented each chemical compound in SMILES (Simpliﬁed Molecu-
lar Input Line Entry System) strings [37] in order to analyze their chemical
structure. We used Pybel which is a Python module to access OpenBabel
toolkit [38], to calculate the ﬁngerprints of chemical compounds represented
by SMILES. Each chemical compound was deﬁned with 3 diﬀerent binary
vectors, corresponding to 3 types of ﬁngerprints formats provided by Python
Pybel module:
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• FP2 is a path-based ﬁngerprint that investigates linear segments of size
1 to 7 atoms
• FP3 uses the SMART strings in patterns.txt
• FP4 uses the SMARTS strings in SMARTS_InteLigand.txt
Even though one can add its own queries to the above stated ﬁles (pat-
terns.txt etc.), we did not add any additional substructure to these ﬁles.
After calculating ﬁngerprints binary data for each of the chemical com-
pound, we used Tanimoto coeﬃcient to calculate structural similarity be-
tween drug pairs. However, another metrics such as Hamming distance, Dice
coeﬃcient [12] and so on, are able to be used.
4.5.3 Side eﬀects similarity
Then, we wanted to compare similarities found in the drug similarity network
to side eﬀect similarities of chemical compounds.
In order to obtain the side eﬀect information pertaining to chemical com-
pounds, we used meddra adverse eﬀects data from Side Eﬀect Resource,
SIDER 2 [39]. The number of common chemical compounds between Hillen-
meyer et al. compounds and SIDER compounds are 53 . SIDER provides
4199 diﬀerent side eﬀects related to chemical compounds.
We formed a vector for each of 53 chemical compounds that consists of
binary values, 0 or 1 where 1 represents the presence of a particular side
eﬀect, and 0 represents the absence of it. The distance for each drug pair was
subsequently calculated by simply counting the shared side eﬀects between
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two drugs. Then, we compared side eﬀect similarities of drug pairs to the
number of similar or diﬀerent edges between drug pairs.
5 Results & Discussions
5.1 Veriﬁcation of Deletion Strain-Drug Network
In the deletion strain-drug network, there are 6013 nodes which comprise
5681 deletion strains and 332 conditions, consisting of 326 chemical com-
pounds and 6 environmental stress conditions. The edge number of the
network is 66400 where half of them are resistance edges and the other half
are sensitivity edges.
As a result of quality assessment 1 , if 2 drugs have an S relationship
with the same set of deletion strains, we observed that these 2 drugs will
also have an R relationship with another set of deletion strains, compared
to the random. We called these types of relations as SS and RR motifs
(See Figure 10) that the correlation result and plot for RR and SS motifs of
drug pairs are given in Table 2 and Figure 13, respectively. This observation
proves the biological meaning of resistance interactions.
The results for quality assessment 2 are given in Table 3, where `fold
enrichment' value shows the enrichment and depletion values of the motifs in
comparison to the randomized versions of the network. We found all p-values
equal to 0 . We, however, are able to only guarantee that p-values are lower
than 10−3due to making 1000 randomizations. As all of p-values are lower
than the cutoﬀ p-value 0 .0035 calculated in Section 4.4.1, we can say that
all of the higher order motifs are signiﬁcant.
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In the left half of Motif1 and Motif7 , 2 drugs have same response to the
same strain as shown in Figure 11. Thus, in the right half part, we expect
to see the same response, too. As both of the drugs have also resistance
edges and sensitivity edges to the same strain in the right half of Motif1 and
Motif7 , respectively, we expect these motifs to be enriched. However, in the
left half of Motif2 and Motif6 , drugs show diﬀerent responses to the same
deletion, hence, we expect to see these diﬀerent responses in the right half,
too. However, in the right half parts of these motifs, both drugs show same
responses. Therefore, we expect these motifs to be depleted. In the left half
of Motif3 , both drugs have same relationships to the same strain, hence, in
the right half part, we expect to see this same response. Since both drugs
have sensitivity edges to the same strain in the right half part of Motif3 , as
we expected, it is enriched. On the other hand, in the left half parts ofMotif4
and Motif5 , drugs have diﬀerent responses. Therefore, we expect to observe
these diﬀerent responses in the right half of these motifs, too. As both drugs
have also inverse relationships in the right, these motifs are enriched.
In conclusion, all of the values pertaining to the higher order motifs prove
that this deletion strain-drug network is robust, and make biological sense
about drug mechanism of action.
correlation p-value
0 .371 < 10−4
Table 2: Correlation between SS and RR motifs of drug pairs as a result of
quality assessment 1
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Figure 13: Correlation plot for SS and RR motifs of drug pairs. Every dot
in the plot represents a single drug pair. x-axis demonstrates the SS motif
number of the corresponding drug pair (the number of deletion strains that
both drugs in the pair have sensitivity relationships with), whereas y-axis
shows the RR motif number of that drug pair (the number of deletion strains
that both drugs in the pair have resistance relationships with).
Motif 1 Motif 2 Motif 3 Motif 4 Motif 5 Motif 6 Motif 7
p-value < 10−3 < 10−3 < 10−3 < 10−3 < 10−3 < 10−3 < 10−3
fold enrichment 2 .270 0 .951 1 .777 1 .084 1 .491 0 .898 1 .991
Table 3: Quality assessment 2 result for higher order motifs in the deletion
strain-drug network. The occurrences of higher order motifs in the real net-
work are compared to the occurrences of those in random networks. The
fold enrichment value for each motif which represents how many times the
corresponding motif is enriched or depleted in the real network, indicates
that the higher order motifs are biologically meaningful.
5.2 Drug Similarity Network
There are totally 162 nodes (drugs), 504 similar edges and 317 diﬀerent
edges in the drug similarity network. Yellow edges represent similar relation-
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ship between drug pairs, whereas blue edges represent diﬀerent relationship.
In Figure 14, the blue and purple circular nodes show the same drug in dif-
ferent concentration levels. As expected, they were found similar to each
other in our network. The green diamond nodes in the right upper con-
nected component form a clique, and show drugs found similar to each other
even though their chemical structures based on FP2 ﬁngerprint are diﬀerent
(Tanimoto coeﬃcient< 0.2) except 2 drug pairs. However, it is noteworthy
to state that their chemical structures based on FP3 and FP4 ﬁngerprints
are similar for all drug pairs in that clique (Tanimoto coeﬃcient≥ 0 .2 ). 3-
vertex, 4-vertex and 5-vertex cliques found in connected components except
the giant component, are shown with diﬀerent colored and shaped nodes in
this ﬁgure. The correlation result and plot for similar and diﬀerent edges
between drug pairs are given in Table 4 and Figure 15, respectively.
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Figure 14: Drug similarity network. Force directed layout is used to draw
the network. Nodes are compounds. Yellow edges represent similar relation-
ship between drug-pairs, whereas blue edges represent diﬀerent relationship.
The blue and purple nodes with circle shape show the same drug in diﬀerent
concentration levels. The drugs found in diﬀerent cliques of connected com-
ponents except the giant component, are represented with diﬀerent colors




−0 .110 < 10−4
Table 4: Correlation between similar and diﬀerent edges between drug pairs
in the drug similarity network
Figure 15: Correlation plot for similar and diﬀerent edges between drug
pairs in the drug similarity network. Every red dot in the plot represents
a drug pair. x-axis shows the similar edge number between drugs in the
corresponding drug pair, whereas y-axis shows the diﬀerent edge number
between them.
The results for quality assessment 2 are given in Table 5 where `fold
enrichment' value shows the enrichment and depletion values of the motifs in
comparison to the randomized versions of the network. Likewise the deletion
strain-drug network, we again found all p-values equal to 0 . However, we are
able to only guarantee that p-values are lower than 10−3due to making 1000
randomizations. As all of p-values are lower than the cutoﬀ p-value 0 .006
calculated in Section 4.5, we can say that all of the higher order motifs are
signiﬁcant.
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In order to interpret the signiﬁcance of fold enrichment values, ﬁrst, we
can simply think that drugA and drugC in Figure 12 are similar to each
other. If drugA is diﬀerent from drugB, we expect drugC to be diﬀerent
from drugB. As we expect, Motif 2 is enriched. However, we do not expect
drugC to be similar to drugB. Therefore, as we expected, it is depleted in
Motif 3. Moreover, we expect Motif1 and Motif4 to be enriched because all
of the edges are in the same type. As Motif1 could not be observed in the
real network even though it was encountered in randomized versions of the
real network, fold enrichment value for Motif1 was found as 0 .
Motif 1 Motif 2 Motif 3 Motif 4
p-value < 10−3 < 10−3 < 10−3 < 10−3
fold enrichment 0 .0 6 .926 0 .059 4 .650
Table 5: Quality assessment result for higher order motifs of the drug sim-
ilarity network. The occurrences of higher order motifs in the real network
are compared to the occurrences of those in random networks. The fold
enrichment value for each motif which represents how many times the corre-
sponding motif is enriched or depleted in the real network, indicates that the
higher order motifs are biologically meaningful. The fold enrichment value
for Motif 1 is 0 because it is not observed in the real network even though
it is encountered in random networks.
In conclusion, all of these observations pertaining to the drug similarity
network prove the robustness of the network. Network visualization of drug
similarity network supplies an important source to understand drug-drug
relations and drug mechanism of action [25].
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5.2.1 Network properties
The plots of degree distribution function, P(k) (See Section 2.4.1) shown in
Figure 16 and the clustering coeﬃcient function, C (k) (See Section 2.4.2)
shown in Figure 17 demonstrate neither random network's properties nor
scale-free network's properties exactly. However, as we mentioned in Section
2.4.3, the majority of drugs may have a few interactions, whereas the mi-
nority of them are highly connected, representing network hubs as shown in
Figure 16. Moreover, the degree distribution P(k) approximates a power law,
P(k) ∼ k−γ where γ equals to 2 .64 . Since 2 < γ < 3 , the hubs are relevant
and the largest hub is linked with a small number of nodes [4]. Therefore, we
are able to strongly conclude that the drug-similarity network is a scale-free
network.
Maximum degree is 47 which means the hub that has the largest link
number, has connections to 47 drugs. It proves the above statement that
the largest hub is connected to small fraction of all nodes. The largest hub of
the network is berberine chloride. Properties of the largest10 hubs are given
in Table 6. We could not observe any relation between molar mass of a com-
pound and being a hub. However, their chemical structures, especially based
on FP3 ﬁngerprints format, are highly similar where Tanimoto coeﬃcients
between drug pairs are at least 0 .2 , most of the times > 0 .4 . Moreover, if
we sort the drugs according to the PageRank, the top 10 PageRank belong
to the largest 10 hubs because unlike in the directed networks, in undirected
networks, PageRank is proportional to degree of nodes, as a result, does not
give any information related to considerable nodes [32]. On the other hand,
the projection of these drugs within the network is demonstrated in Figure
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21. In the below network of Figure 21, the complete subgraph of these drugs
are able to be seen clearly that means all nodes representing the largest
10 hubs of the drug similarity network, have also connections between each
others.
On the other hand, minimum degree of the network is 1 , whereas the
average degree < k > is (2 ∗ L)/N = (2 ∗ 821)/162 = 10.14 where L and N
denote the edge number and the node number, respectively (For more detail,
see Section 2.4.1).
There are 99 drugs in the largest connected component of the network
which is also called giant component [25]. This giant component size of the
real network is signiﬁcantly smaller than those of randomized versions with
fold enrichment= 0.62 and p < 10−3 . This result suggests that certain drugs
form local clusters within the network.
As seen in Figure 18, maximum clustering coeﬃcient of the network is
1 , whereas the minimum is 0 . On the other hand, the average clustering
coeﬃcient, < C > of the network is 0 .46 that identiﬁes the overall aptitude
of nodes to generate clusters [4]. The average clustering coeﬃcient, < C >
of the real network is signiﬁcantly larger than those of randomized versions
with fold enrichment= 3.20 and p < 10−3 . Therefore, the drug similarity
network can be considered as small-world that there are a few links between
each pair of nodes in the network (See Section 2.4.7).
Betweenness centrality and PageRank scores of the drug similarity net-
work are given in Figure 19 and Figure 20, respectively that maximum be-
tweenness centrality and PageRank score were found as 687 .84 and 2 .89 ,
respectively which belong to the largest hub of the network, berberine chlo-
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ride, as expected.
Figure 16: P(k): Degree distribution of a selected node with k links in the
drug similarity network. The majority of drugs have a few interactions,
whereas the minority of them are highly connected, representing network
hubs. The degree distribution P(k) approximates a power law, P(k) ∼ k−γ
where γ equals to 2 .64 . Since 2 < γ < 3 , the hubs are relevant and the
largest hub is linked with a small number of nodes [4]. Therefore, we are
able to strongly conclude that the drug-similarity network is a scale-free
network.
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Figure 17: C(k): Average clustering coeﬃcient of the nodes with k links in
the drug similarity network
Figure 18: Frequency of clustering coeﬃcient of each node in the drug simi-
larity network. Maximum clustering coeﬃcient of the network is 1 , whereas
the minimum is 0 . On the other hand, the average clustering coeﬃcient,
< C > of the network is 0 .46 that identiﬁes the overall aptitude of nodes to
generate clusters [4]. The average clustering coeﬃcient, < C > of the real
network is signiﬁcantly larger than those of randomized versions with fold
enrichment= 3.20 and p < 10−3 . Therefore, the drug similarity network can
be considered as small-world that there are a few links between each pair of
nodes in the network.
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Minimum Betweenness Centrality 0 .00
Maximum Betweenness Centrality 687 .84
Average Betweenness Centrality 42 .37
Figure 19: Betweenness centrality of the drug similarity network
Minimum PageRank 0 .20
Maximum PageRank 2 .89
Average PageRank 1 .00
Figure 20: PageRank frequency of the drug similarity network
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Figure 21: Subgraph of the largest 10 hubs in the drug similarity network.
Degree sorted circle layout is used to draw the network. Nodes are com-
pounds. Yellow edges represent similar relationship between drug-pairs,
whereas blue edges represent diﬀerent relationship. In the above network,
the drugs representing the largest 10 hubs are colored with red, and all the
connections of these drugs are given. In the below network, a complete sub-
graph of these drugs is given where all drugs are connected to each other.
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Drug name PubChem (CID) Degree 2D Structure Molecular formula Molar mass PageRank
berberine chloride 12456 47 C20H18ClNO4 371 .81g/mol 2 .89
caspofungin 151068 44 C52H88N10O15 1093 .31g/mol 2 .57
dyclonine 3180 43 C18H27NO2 289 .41g/mol 2 .46
pp1 1400 41 C16H19N5 281 .36g/mol 2 .45
bithionol 2406 39 C12H6Cl4O2S 356 .05g/mol 2 .38
fendiline hydrochloride 5702162 39 C23H26ClN 351 .91g/mol 2 .16
aphidicolin glycinate 130315 38 C22H38ClNO5 431 .99g/mol 2 .17
lovastatin 53232 37 C24H36O5 404 .54g/mol 2 .09
pp2 4878 35 C15H16ClN5 301 .77g/mol 1 .93
benomyl 28780 34 C14H18N4O3 290 .32g/mol 1 .87
Table 6: Properties of the largest 10 hubs of the drug similarity network
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5.2.2 An 8-vertex well connected component
As seen in Figure 14, there is a well connected component with 8 nodes in
the drug similarity network. Here, we expanded this component by showing
the interactions between the drugs in the component and deletion strains
as shown in Figure 22, which is a subgraph of deletion strain-drug network.
Drugs and deletion strains are nodes of the network. Green edges repre-
sent the sensitivity interactions between drugs and deletion strains, whereas
red edges represent the resistance edges. The 8 drugs are shown with blue
squares. The nodes shown with black circles are deletion strains. However,
the shared deletion strains that all 8 compounds have resistance relation-
ships, are shown with pink circles. As the deletion strain-drug network is
bipartite, there is not any interaction between deletion strains or drugs it-
self. The properties of drugs in the component are given in Table 7. The
betweenness centrality scores of these drugs are extremely low as expected
because these drugs form a component where any additional drug has no
access to these drugs.
Aclavine hydrochloride is one of them whose therapeutic indication is in-
fection, and therapeutic uses is as an agent for anti-infection [40]. Estrone is
one type of estrogens including estradiol. As an hormone replacement ther-
apy, estradiol acetate is used to avoid the indications of menopause in women
[41, 42, 43, 44]. On the other hand, Estrone acetate is also used in hormonal
therapeutics. Dopamine takes a role as an antagonist of protein dopamine
receptor D2 (one of ﬁve G protein-coupled receptors) in homo sapiens [40].
While it is used in treatment of dopamine receptor's physiological eﬀects,
it has also been showed that dopamine takes a role in pain processing in
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central nervous system [45]. Therapeutic indication and therapeutic use of
piperidolate hydrochloride are pain and analgesic, respectively. In therapeu-
tic indications such as pain and inﬂammation, tolfenamic acid is also used
as an analgesic and anti-inﬂammatory agent. Phenoxybenzamine hydrochlo-
ride takes a role as an antagonist of proteins with alpha-adrenergic receptor
activity. It is used as an anti-hypertensive agent in hypertension indication
[40].
Consequently, we are able to infer that the drugs in this well connected
component are somehow share certain therapeutics indications and uses which
leads us to have intuition that yeast cells show similar response to drugs hav-
ing similar therapeutics eﬀects (See Section 6).
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Figure 22: A well connected component with 8 nodes in the drug similarity
network. Nodes are drugs and deletion strains of the drug similarity network.
Green edges represent the sensitivity interactions between drugs and deletion
strains, whereas red edges represent the resistance edges. The 8 drugs in the
well connected component are shown with blue squares. The nodes shown
with black circles are deletion strains. However, the shared deletion strains
that all 8 compounds have resistance relationships, are shown with pink
circles.
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Drug name PubChem (CID) 2D Structure Molecular formula Molar mass Betweenness centrality
aklavin hydrochloride 264889 C30H36ClNO10 606 .06g/mol 0 .00
estradiol acetate 157050 C20H26O3 314 .42g/mol 0 .17
domperidone 3151 C22H24ClN5O2 425 .91g/mol 0 .17
piperidolate hydrochloride 8520 C21H26ClNO2 359 .89g/mol 0 .17
estrone acetate 3273 C20H24O3 312 .40g/mol 0 .17
estradiol propionate 19571 C21H28O3 328 .45g/mol 0 .17
tolfenamic acid 5507 C14H12ClNO2 261 .70g/mol 0 .17
phenoxybenzamine hydrochloride 5284441 C18H23Cl2NO 340 .29g/mol 0 .00
Table 7: Properties of drugs in the well connected component with 8 nodes
of the drug similarity network
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5.2.3 Comparison with chemical structural similarities
Once we proved robustness of the drug similarity network, we wanted to
discover reasons of the observed similarities. First, we thought that chemical
structural similarities of the compounds may shed light into ﬁnding a relation
with the drug similarity network.
We calculated the correlation between chemical structural similarities of
drug pairs and the number of similar edges or the number of diﬀerent edges
that drug pairs are linked with (also means the number of shared deletion
strains. For more detail, see Section 4.5).
165 edges out of 504 similar edges and 71 edges out of 317 diﬀerent
edges between drug pairs were found as sharing chemical structural similar-
ity with Tanimoto coeﬃcient≥ 0 .2 . The results given in Table 8 and Table
9 demonstrate that there is a signiﬁcant correlation between chemical struc-
tural similarity and similar edge numbers of drug pairs. However, we were
not able to observe any correlation between chemical structural similarity
and diﬀerent edge numbers of drug pairs.
Then, we tried to create a regression model to predict the chemical struc-
tural similarity score using similar and diﬀerent edge numbers of each drug
pair which is a multiple linear regression problem. The results are given in
Table 10. Even though the coeﬃcient of similar edge number is substantially
low, its p-value is highly signiﬁcant.
Therefore, the chemical structural similarity may be used to explain sim-
ilar relationships between drug pairs.
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FP2 FP3 FP4
correlation 0 .35 0 .19 0 .31
p-value < 10−4 < 10−4 < 10−4
Table 8: Correlation between chemical structural similarities and similar edge
numbers between drug pairs of the drug similarity network
FP2 FP3 FP4
correlation −0 .04 −0 .04 −0 .02
p-value < 0 .55 < 0 .52 < 0 .78
Table 9: Correlation between chemical structural similarities and diﬀerent
edge numbers between drug pairs of the drug similarity network
Coeﬃcient Standard deviation p-value
similar edge number 0 .001 5 .83e − 005 < 1 .51e − 070
diﬀerent edge number −2 .33e − 004 1 .19e − 004 < 0 .05
Table 10: A regression model for chemical structural similarity based on FP2,
by using similar and diﬀerent edge numbers between drug pairs of the drug
similarity network
5.2.4 Comparison with side eﬀect similarities
We also had an intuition that side eﬀect similarities of drugs may cause same
response on the cell, hence it may contribute to be able to gain insight into
observed similarities and dissimilarities in the drug similarity network.
As we have side eﬀect information only for 53 drugs of Hillenmeyer et al.
dataset, we were only able to examine relationships of 1378 drug pairs for the
side eﬀects analysis. 33 similar relationships and 11 diﬀerent relationships
out of 1378 relationships of drug pairs were found signiﬁcant (p − value <
9.09e−7 and fold enrichment> 5 ), hence these interactions were involved in
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similar edge numbers diﬀerent edge numbers
correlation 0 .14 −0 .46
p-value < 0 .46 < 0 .16
Table 11: Correlation between side eﬀect similarities and similar or diﬀerent
edge numbers between drug pairs of the drug similarity network
Coeﬃcient Standard deviation p-value
similar edge number −0 .02 0 .05 < 0 .73
diﬀerent edge number 0 .41 0 .15 < 0 .006
Table 12: A regression model for side eﬀect similarity by using similar and
diﬀerent edge numbers between drug pairs of the drug similarity network
the drug similarity network. Likewise the chemical structural similarity, we
calculated the correlation between side eﬀects similarities of drug pairs and
the number of similar edges or the number of diﬀerent edges of drug pairs.
The results given in Table 11 demonstrate that we were not able to observe
any correlation between side eﬀect similarities and similar edge numbers of
drug pairs. On the other hand, there is a correlation between side eﬀect
similarities and diﬀerent edge numbers of drug pairs. Its p-value, however,
is not signiﬁcant.
Likewise in chemical structural similarity, we evaluated multiple linear
regression to predict the side eﬀect similarity score using similar and diﬀerent
edge numbers of each drug pair. The results are given in Table 12. As seen in
the table, the coeﬃcient for similar edge numbers is not signiﬁcant. However,
the coeﬃcient for diﬀerent edge numbers is signiﬁcant and large enough to
be able to infer that side eﬀect similarity increases when the diﬀerent edge
number increases.
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5.2.5 Comparison with MSB Cokol 2012 dataset
Cokol et al. [46] examined 175 drug pair (25 more self-self drug pairs were
also examined for control) combinations from 33 diﬀerent chemical com-
pounds in S. cerevisiae in order to assess synergistic (S), antagonistic (A)
and independent (I) interactions between drugs. 108 interactions out of 175
interactions which are between 25 drugs out of 33 drugs, were also examined
in Hillenmeyer et al. dataset.
There is not any signiﬁcant similar interactions out of 108 interactions
that will subsequently constitute the drug similarity network. However, we
observed 5 signiﬁcant diﬀerent interactions in the Cokol et al. dataset, hence,
also appear in the drug similarity network. 3 out of 5 of these diﬀerent
interactions were also found as antagonistic in the Cokol et al., whereas 2
out of 5 interactions were referred as independent. Independent interactions
are between 5 ﬂuorouracil - benomyl and 5 ﬂuorouracil - fk506. Antagonistic
interactions are between benomyl - staurosporine, calyculin a - latrunculin
and rapamycin - fk506.
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6 Conclusions and Future Work
In this thesis, we proposed a method in order to understand drug mech-
anism of action. The results of the proposed method suggest similarities
and dissimilarities between certain drug pairs. Once we made several qual-
ity assessments on the network and proved its robustness, we compared the
observed similarities with various orthogonal datasets.
First of all, as a conclusion of comparing the results to chemical structural
similarities of compounds, we concluded that drugs that have similar chemical
structures, may have similar eﬀect on the yeast cell which supports the results
and hypothesis given by Giaever et al. [33] and Hillenmeyer et al. [12] that
cells may show similar response to drugs having similar structures.
On the other hand, we, in some cases, observed that yeast genes show
diﬀerent response to drugs that have similar side eﬀects. Therefore, we are
not able to generalize the drug similarities by only comparing their side eﬀects
to each other. Side eﬀect similarities of drugs cannot explain by itself how
the drug mechanism works within the cell.
Consequently, the suggested drug similarities can be used as a valuable
tool that provides a reasonable selection for further development and test
of unapproved compounds, for instance, compounds that are considered to
have high probability on taking role in treatment of cancer disease but not
FDA-approved, can be chosen from the set of most similar drugs given by
our study to those compounds that drugs in the set are FDA-approved and
widely used in cancer treatment. Therefore, the best candidates can be
pinpointed which further prevent the useless cost of development and test of
compounds unrelated to cancer treatment. This approach also contributes
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us to discover unknown mechanism of a drug from known ones which are
revealed as very similar to the corresponding drug at the end of our study.
Moreover, if a drug has important side eﬀects on the cell even though it is
used in treatment of cancer disease, it can be replaced with another drug very
similar to the corresponding drug in our study, but which has less adverse
eﬀects.
The drug similarity network revealed caspofungin, berberine chloride and
bithionol as more similar to the drugs in the network with having similar
edge degrees > 30 which suggests that these drugs may have same eﬀect
on the yeast cells with most of other drugs. On the other hand, pp1 and
pp2 are the drugs that were found as the most diﬀerent ones within the
network. Therefore, it may be inferred that they may have a speciﬁc role in
the mechanism of cell functions that many of other drugs do not have this
speciﬁcity.
Additionally, we found a set of genes called MDS genes whose deletions
make yeast cells resistant to multiple drug conditions, hence the correspond-
ing deleted genes are required for sensitivity to diverse perturbations. MDS
genes were found as highly enriched for RNA metabolism related functions
which contributes us to understand the working mechanism of cell functions
in response to chemical perturbations.
As a future work, we are planning to cluster the drugs in the drug sim-
ilarity network according to Anatomical Therapeutic Chemical (ATC) clas-
siﬁcation, and then compare the ATC clusters to the observed similarities.
Since we found drugs of the 8-vertex well connected component as sharing
certain therapeutic indications, our intuition is that drugs which are in same
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ATC cluster, are most likely similar to each other. In other words, yeast cells
show same response to the drugs which have same therapeutic eﬀect on the
cell.
On the other hand, as the drug similarity network, a gene similarity net-
work can also be constructed from deletion strain-drug network that may
contribute to highlight gene functions within the cell. Comparing the simi-
larities found in the gene similarity network to genetic interactions between
gene pairs or protein interactions may also help to explain how the genetic
or protein interactions occur.
Finally, we want to test similarities of drugs found in cliques of connected
components of the drug similarity network except those of the giant compo-




• MDR - Multi-drug resistance
• MDS - Multi-drug sensitive
• HOP - Haploinsuﬃciency Proﬁling
• HIP - Homozygous Proﬁling
• MSP - Multi-copy Suppression Proﬁling
• SGA - Synthetic Genetic Analysis
• ORF - Open Reading Frames
• ATC - Anatomical Therapeutic Chemical
• SIDER - Side Eﬀect Resource
• SMILES - Simpliﬁed Molecular Input Line Entry System
• MSB - Molecular Systems Biology
• GO - Gene Ontology
• HTC - High Throughput Screening
• FDA - Food and Drug Administration
• FP - Fingerprints
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